8DYI

IL17A homodimer bound to Compound 5


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.28 Å
  • R-Value Free: 0.311 
  • R-Value Work: 0.272 
  • R-Value Observed: 0.274 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site.

Goedken, E.R.Argiriadi, M.A.Dietrich, J.D.Petros, A.M.Krishnan, N.Panchal, S.C.Qiu, W.Wu, H.Zhu, H.Adams, A.M.Bodelle, P.M.Goguen, L.Richardson, P.L.Slivka, P.F.Srikumaran, M.Upadhyay, A.K.Wu, B.Judge, R.A.Vasudevan, A.Gopalakrishnan, S.M.Cox, P.B.Stoll, V.S.Sun, C.

(2022) Sci Rep 12: 14561-14561

  • DOI: https://doi.org/10.1038/s41598-022-18760-1
  • Primary Citation of Related Structures:  
    8DYF, 8DYG, 8DYH, 8DYI

  • PubMed Abstract: 

    Anti-IL17A therapies have proven effective for numerous inflammatory diseases including psoriasis, axial spondylitis and psoriatic arthritis. Modulating and/or antagonizing protein-protein interactions of IL17A cytokine binding to its cell surface receptors with oral therapies offers the promise to bring forward biologics-like efficacy in a pill to patients. We used an NMR-based fragment screen of recombinant IL17A to uncover starting points for small molecule IL17A antagonist discovery. By examining chemical shift perturbations in 2D [ 1 H, 13 C-HSQC] spectra of isotopically labeled IL17A, we discovered fragments binding the cytokine at a previously undescribed site near the IL17A C-terminal region, albeit with weak affinity (> 250 µM). Importantly this binding location was distinct from previously known chemical matter modulating cytokine responses. Subsequently through analog screening, we identified related compounds that bound symmetrically in this novel site with two copies. From this observation we employed a linking strategy via structure-based drug design and obtained compounds with increased binding affinity (< 50 nM) and showed functional inhibition of IL17A-induced cellular signaling (IC 50 ~1 µM). We also describe a fluorescence-based probe molecule suitable to discern/screen for additional molecules binding in this C-terminal site.


  • Organizational Affiliation

    AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA. eric.goedken@abbvie.com.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Interleukin-17A
A, B
127Homo sapiensMutation(s): 1 
Gene Names: IL17ACTLA8IL17
UniProt & NIH Common Fund Data Resources
Find proteins for Q16552 (Homo sapiens)
Explore Q16552 
Go to UniProtKB:  Q16552
PHAROS:  Q16552
GTEx:  ENSG00000112115 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ16552
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.28 Å
  • R-Value Free: 0.311 
  • R-Value Work: 0.272 
  • R-Value Observed: 0.274 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 172.938α = 90
b = 30.507β = 102.71
c = 50.239γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
autoPROCdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2022-09-07
    Type: Initial release
  • Version 1.1: 2023-10-18
    Changes: Data collection, Refinement description
  • Version 1.2: 2024-10-23
    Changes: Structure summary